Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20722785 | 1.00 | HSD11B1 (0.41) | HSD11B1JAK1HDAC1CHRM2CHRM1 | |
| SCHEMBL22638945 | 1.00 | HSD11B1 (0.41) | HSD11B1JAK1HDAC1CHRM2CHRM1 | |
| SCHEMBL22638963 | 1.00 | HSD11B1 (0.41) | HSD11B1JAK1HDAC1CHRM2CHRM1 | |
| SCHEMBL23938317 | 0.96 | HSD11B1 (0.37) | HSD11B1JAK1HDAC1CHRM2CHRM1 | |
| SCHEMBL20722677 | 0.85 | GRK2 (0.31) | — | |
| SCHEMBL22645047 | 0.85 | HSD11B1 (0.45) | HSD11B1JAK1HDAC1CHRM2CHRM1 | |
| SCHEMBL22645046 | 0.85 | HSD11B1 (0.45) | HSD11B1JAK1HDAC1CHRM2CHRM1 | |
| SCHEMBL20722543 | 0.82 | HSD11B1 (0.43) | HSD11B1JAK1HDAC1CHRM2CHRM1 | |
| SCHEMBL22645049 | 0.82 | HSD11B1 (0.43) | HSD11B1JAK1HDAC1CHRM2CHRM1 | |
| SCHEMBL20722608 | 0.82 | MAPT (0.48) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162888-B2 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| CN-112867712-B | Carboxamide as ubiquitin-specific protease inhibitor | 瓦洛早期发现股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | HSD11B1 4134/4885JAK1 1927/4885HDAC1 130/4885 |
| US-12162888-B2 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | HSD11B1 4134/4885JAK1 1927/4885HDAC1 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.